

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): March 5, 2015

Merit Medical Systems, Inc.

(Exact name of registrant as specified in its charter)

Utah

(State or other jurisdiction of
incorporation or organization)

0-18592

(Commission
File Number)

87-0447695

(I.R.S. Employer
Identification No.)

1600 West Merit Parkway

South Jordan, Utah

(Address of principal executive offices)

84095

(Zip Code)

(801) 253-1600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 – Regulation FD Disclosure.

On March 5, 2015, Merit Medical Systems, Inc. (the “Company”) will conduct its Investor Day presentation at the Company’s headquarters in South Jordan, Utah. During the presentation, members of the Company’s management intend to discuss the Company’s operations, performance and outlook. The Company’s management also intends to discuss the Company’s expectations regarding various measures of the Company’s financial performance.

The Investor Day presentation is scheduled to begin at 9:00 a.m., Mountain time, on March 5, 2015. Investors, analysts, shareholders and the general public are invited to access a live webcast of the presentation over the Internet via the “Investors” page on the Company’s website (www.merit.com). The presentation will also be archived and accessible via the “Investors” page on the Company’s website (www.merit.com) following the completion of the webcast. Website addresses are included in this report for reference only. The information contained on the Company’s website is not part of this report and is not incorporated by reference into this report.

A copy of a press release, dated March 5, 2015, addressing the Company’s three-year plan to be discussed during the Investor Day presentation, is attached as Exhibit 99.1 to this report. A copy of the printed materials to be presented by the Company’s management during the Investor Day presentation is attached as Exhibit 99.2 to this report.

The information furnished pursuant to Item 7.01 of this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into future filings by the Company under the Securities Act of 1933, as amended, or under the Exchange Act, unless the Company expressly sets forth in such future filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release, dated March 5, 2015, entitled "Merit Medical Details Three-Year Plan to Accelerate Profitable Growth"
99.2	Merit Medical Systems, Inc. Investor Day presentation slides

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MERIT MEDICAL SYSTEMS, INC.

Date: March 5, 2015

By: /s/ Kent W. Stanger
Kent W. Stanger
Chief Financial Officer, Secretary, Treasurer

EXHIBIT INDEX

EXHIBIT NUMBER	DESCRIPTION
99.1	Press Release, dated March 5, 2015, entitled "Merit Medical Details Three-Year Plan to Accelerate Profitable Growth"
99.2	Merit Medical Systems, Inc. Investor Day presentation slides



1600 West Merit Parkway • South Jordan, UT 84095

Telephone: 801-253-1600 • Fax: 801-253-1688

PRESSRELEASE

FOR IMMEDIATE RELEASE

Date: March 5, 2015
Contact: Anne-Marie Wright, Vice President, Corporate Communications
Phone: (801) 208-4167 e-mail: awright@merit.com Fax: (801) 253-1688

Merit Medical Details Three-Year Plan to Accelerate Profitable Growth

Company Holds First Investor Day

Projects Revenues to Approach \$635 Million in FY2017

Expects Improvement in Non-GAAP Net Income of over 50% by 2017

Foresees Improvement in Non-GAAP Gross Margin of up to 240 Basis Points

Anticipates Improvement in GAAP Net Income of over 85% by 2017

SOUTH JORDAN, Utah, March 5, 2015 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq:MMSI) Chairman and Chief Executive Officer Fred P. Lampropoulos and other company leaders will detail Merit's three-year strategic growth plan today at its first Investor Day, hosted at the company's headquarters in South Jordan, Utah.

"We look forward to discussing the details of our three-year plan this morning," Lampropoulos said. "We believe the overview will present a clear vision of our goals for overall improvement in every aspect of our company. Business growth does not always fit nicely into calendar years and often bridges consecutive years, such as our expansion in Mexico and U.S. plant consolidation. Also, many of our R&D activities now require several years of development due to testing requirements and government submissions and protocols. Our presentation today is intended to explain our plan for operational efficiency and new projects we believe will substantially impact our company. We thank those who will attend the event in Utah today and the many who will be listening to our webcast."

In Merit's three-year business plan, the company has established the following key financial goals:

NON-GAAP	2014	2015	2016	2017
Sales	\$510M	\$535-\$545M	\$580-\$590M	\$625-\$635M
Gross Margin	46.4%	46.5-47.5%	47.0-48.0%	47.8-48.8%
Income from Operations	11.1%	10.9-11.9%	11.5-12.5%	12.4-13.4%
EPS	\$0.78	\$0.85-\$0.89	\$0.95-\$1.01	\$1.10-\$1.18
EBITDA	\$78.1M	\$84-\$88M	\$90-\$96M	\$98-\$106M
Free Cash Flow	\$19M	\$20-\$25M	\$30-\$35M	\$35-40M

WEBCAST

Merit management will discuss Merit's three-year business plan in more detail today, (Thursday, March 5, 2015) at 11:00 a.m. Eastern (10:00 a.m. Central, 9:00 a.m. Mountain, and 8:00 a.m. Pacific). A live webcast of management's presentation, including slides, will be accessible at www.merit.com and will be archived on Merit's website on the Investors page.

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional and diagnostic procedures, particularly in cardiology, radiology and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 200 individuals. Merit employs approximately 3,100 people worldwide, with facilities in South Jordan, Utah; Pearland, Texas, Richmond, Virginia; Malvern, Pennsylvania; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; and Rockland, Massachusetts.

This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this release, other than statements of historical fact, are "forward-looking statements", including any projections of earnings, revenues or other financial items, any statements regarding Merit's plans and objectives for future operations, any statements concerning proposed new products, any statements regarding the integration, development or commercialization of Merit's business or any assets acquired or to be acquired from other parties, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All forward-looking statements, including financial projections, included in this release are made as of the date hereof and are based on information available to Merit as of such date. Merit assumes no obligation to update or disclose revisions to any forward-looking statement. In some cases, forward-looking statements can be identified by the use of terminology such as "may," "will," "likely," "expects," "plans," "anticipates," "intends," "believes," "estimates," "projects," "forecast," "potential," "plan" or "continue," or the negative thereof or other comparable terminology. Forward-looking statements are based on Merit's current beliefs, expectations and assumptions regarding Merit's business, domestic and global economies, regulatory and competitive environments and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstance that are difficult to predict. There can be no assurance that such beliefs, expectations or assumptions or any of the forward-looking statements will prove to be correct, and actual results will likely differ, and could differ materially, from those projected or assumed in the forward-looking statements. Merit's future financial and operating results and condition, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including risks relating to possible infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; product recalls and product liability claims; potential restrictions on Merit's liquidity or Merit's ability to operate its business by its current debt agreements; potentially significant adverse changes in, or Merit's failure to comply with, governing regulations; international economic conditions affecting Merit's business and operating results; greater governmental scrutiny and increasing regulation of the medical device industry; termination or interruption of relationships with Merit's suppliers or failure of such suppliers to perform; expenditures relating to research, development, testing and regulatory approval or clearance of Merit's products and the risk that such products may not be developed successfully or approved for commercial use; laws targeting fraud and abuse in the healthcare industry; the potential imposition of fines, penalties, or other adverse consequences if Merit's employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; healthcare reform legislation affecting Merit's business, operations or financial condition; modification or limitation of governmental or private insurance reimbursement policies; fluctuations in foreign currency exchange rates; increases in the prices of commodity components or loss of supply; Merit's potential inability to successfully manage growth through acquisitions, including the inability to commercialize technology acquired through completed, proposed, or future acquisitions; Merit's need to generate sufficient cash flow to fund its debt obligations, capital expenditures, and ongoing operations; concentration of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's existing products obsolete; volatility in the market price of Merit's common stock; disruption of critical information systems or material breaches in the security of Merit's systems; changes in key personnel; fluctuations in Merit's effective tax rate; work stoppage or transportation risks; failures to comply with applicable environmental laws; disruption of Merit's manufacturing operations, including as a result of severe weather conditions or natural disasters; and other factors referenced in Merit's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the Year Ended December 31, 2014. All forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements.

The financial projections set forth in this release are based on a number of assumptions, estimates and forecasts. The inaccuracy of any one of those assumptions, estimates or forecasts could materially impact Merit's actual financial results. Inevitably, some of those assumptions, estimates or forecasts will not occur and unanticipated events and circumstances will occur subsequent to

the date of this presentation. In addition to changes in the underlying assumptions, Merit's future performance is subject to a number of risks and uncertainties, known and unknown, with respect to its existing and proposed business, and other factors that may cause Merit's actual results or performance to be materially different from any predicted or implied. Merit's future performance is dependent upon these significant estimates and the existence or absence of circumstances that have not yet occurred and which may not occur or which may have different consequences than those now assumed or anticipated. Although Merit has attempted to identify important assumptions in the financial projections, there may be other factors that could materially affect Merit's actual financial performance, and no assurance can be given that all material factors have been considered in the preparation of the financial projections. Accordingly, readers should not place undue reliance on such projections. Future operating results are, in fact, impossible to predict.

###





VISION. GROWTH. PROFITABILITY.

INVESTOR DAY | March 5th 2015

FRED P. LAMPROPOULOS
CHAIRMAN & CHIEF EXECUTIVE OFFICER

KENT W. STANGER
CHIEF FINANCIAL OFFICER



DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

This presentation includes "forward-looking statements" as defined within applicable securities laws and regulators. All statements in this presentation, other than statements of historical fact, are "forward-looking statements", including any projections of earnings, revenues or other financial items, any statements regarding our plans and objectives for future operations, any statements concerning proposed new products or services, any statements regarding the integration, development or commercialization of our business, any statements regarding future economic conditions or performance, and any statements of assumptions underlying any of the foregoing. All forward-looking statements, including financial projections, included in this presentation are made as of the date of this presentation, and are based on information available to us as of such date. We assume no obligation to update or disclose revisions to any forward-looking statement. In some cases, forward-looking statements can be identified by the use of terminology such as "may," "will," "likely," "expects," "plans," "anticipates," "intends," "believes," "estimates," "projects," "forecast," "potential," "plan" or "continue," or other comparable terminology. Forward-looking statements are based on our current beliefs, expectations and assumptions regarding our business, domestic and global economies, regulatory and competitive environments and other future conditions. There can be no assurance that such beliefs, expectations or assumptions or any of the forward-looking statements will prove to be correct, and actual results will likely differ, and could differ materially, from those projected or assumed in the forward-looking statements. Our future financial and operating results and condition, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including risks relating to possible allegations of infringement of the intellectual property rights of others; protection of our own proprietary technology; product recalls and product liability claims; restrictions and limitations imposed by our debt agreements and instruments; compliance with governing regulations; international economic conditions; greater governmental scrutiny and increasing regulation of the medical device industry; termination or disruption of relationships with our suppliers; research and development activities; regulatory approval or clearance of our products and the risk that such products may not be developed successfully or approved for commercial use; concentration of our revenues among a few products and procedures; development of new products and technology that could render our existing products obsolete; volatility in the market price of our common stock; the potential imposition of fines, penalties and other adverse consequences resulting from the violation of domestic or foreign laws or regulations; and other factors referenced in our press releases and in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the Year Ended December 31, 2014. All subsequent forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements.

The financial projections set forth in this presentation are based on a number of assumptions, estimates and forecasts. The inaccuracy of any one of those assumptions, estimates or forecasts could materially impact our actual financial results. Inevitably, some of those assumptions, estimates or forecasts will not occur and unanticipated events and circumstances will occur subsequent to the date of this presentation. In addition to changes in the underlying assumptions, our future performance is subject to a number of risks and uncertainties, with respect to our existing and proposed business, and other factors that may cause our actual results or performance to be materially different from any predicted or implied. Although we have attempted to identify important assumptions in the financial projections, there may be other factors that could materially affect our actual financial performance, and no assurance can be given that all material factors have been considered in the preparation of the financial projections. Accordingly, you should not place undue reliance on such projections. Future operating results are, in fact, impossible to predict.



VISION. GROWTH. PROFITABILITY.

1

Enhance growth
and profitability

2

Optimize operational
capability


3

Target high-growth,
high-return
opportunities

4

Disciplined,
customer-focused
enterprise

Revenue Outlook



Revenue Drivers

Products

- Continued introduction of high-margin products annually
- System selling in key areas such as radial, embolization, cardiac rhythm management, electrophysiology, and peripheral artery disease

Market Share

- Enter complementary product segments while securing existing market positions
- Continue investment in Tier One Global Markets

Sales Model Optimization

- Control of key business processes such as licenses and distribution to build sustainable growth
- Diversified revenue streams: direct, distributor, OEM, and semi-direct

Global Logistical Reach & Revenue Channels





United States Revenue Growth

DIRECT

- Above-market growth rates
- Continued market share gains

3-Year CAGR

7%

OEM

- Focus on technology
- Access to additional revenue streams

3-Year CAGR

25%

ENDOTEK

- Portfolio expansion
- Above-market growth rates

3-Year CAGR

15%

International Tier One Focus



CHINA

Population
1,357,380,000

3-Year CAGR
25%



JAPAN

Population
126,435,000

3-Year CAGR
18%



BRAZIL

Population
202,768,000

3-Year CAGR
17%



SOUTHEAST ASIA Hong Kong & Taiwan

Population
673,981,000

3-Year CAGR
31%




RUSSIA

Population
143,976,000

3-Year CAGR
31%




China Revenue Growth




Gross Margin Outlook

GAAP Percentage of Sales



NON-GAAP Percentage of Sales



Gross Margin Drivers

- Efficient Asset Utilization
- Facility Consolidation
- Insourcing
- Lean Manufacturing



Gross Margin Drivers Global Logistics

- Automation
- Fulfillment
- Shipping
- Digital Initiatives
- Print & Apply



Gross Margin Drivers

Product Mix




Cost Effective Environments



Mexico

- 150 employees as of May 1st
- 500 employees in 3 years
- Rapid response, logistics pipeline
- Improved product economics



Cost Effective Environments



Ireland

- Highly trained workforce
- Favorable incentives
- Research and development
- Manufacturing access to our fastest growing markets



Operating Focus

1

Maximize Operating Leverage

- Focus on financial performance
- Gross margin improvement
- Disciplined expense management

2

Sales Force Efficiency

- Relatively fixed cost, focused sales force
- Effective new product introduction

3

Culture

- Understand. Innovate. Deliver.™
- Cost discipline while preserving quality and innovation

4

Value Per Dollar Spent

- Buying authority
- Shared services
- Capitalize on global scale

Research & Development

MERITMEDICAL
PERIPHERAL INTERVENTION

MERITMEDICAL
CARDIAC INTERVENTION

MERITMEDICAL
ENDOSCOPY



Research & Development Strategy

1

Disciplined Investment

- Develop high margin advanced products and therapies that address underserved, sizable global markets
- Enhance existing portfolios and services

2

Global R&D Centers of Excellence

- Coatings
- Guide Wires
- Catheters
- Sensors
- Embolization
- Stents

3

Clinical Evidence & Value

- Produce clinical evidence that influences health economics
- Clinical trial investment


4

Global Commercialization

- High-growth, high-return markets
- Education
- Adoption
- Measurement for return and effectiveness

Endoscopy

Merit Endotek



Market
Opportunity
\$145M

Portfolio Priorities

- Introduce new, high-margin products
- Secure airway stent market position with optimized, comprehensive product lines
- Offer customers improved balloon dilation, through proprietary balloon design
- Improve patient care and outcomes by offering advanced esophageal stents with integral reflux control valve

Initiatives

- Complete development and launch of ELATION™ Balloon Dilators—representing significant market potential and multi-call point opportunities
- Deliver a differentiated procedural solution and address a larger market size with AEROMini™
- Complete U.S. clinical trial and launch EndoMAXX EVT™

Peripheral Intervention Embolotherapy



Portfolio Priorities

- Interventional Gynecology: UTERINE
- Interventional Oncology: HEPATIC
- Interventional Urology: PROSTATIC
- Interventional Gastroenterology: LEFT GASTRIC

Initiatives

- ask4UFE® patient education
- Clinical differentiation
- Radial education and adoption
- Clinical data: HiQuality, BEST, BEAT
- Key opinion leader development
- Therapeutic adoption through education
- System selling

Peripheral Intervention Merit Biopsy Device



Portfolio Priorities

- Complementary capability from diagnosis to treatment
- Improved sample quality in smaller, lighter device
- Leverage current call point presence

Initiatives

- Needle design and mechanical technology
- Leverages Merit's core strengths
- Training for adoption awareness
- Complete competitive offering

Peripheral Intervention Vascular Stent Graft



Market
Opportunity
\$908M

Portfolio Priorities

- Designed to address an unmet clinical need
- Broad range of diameters and lengths with a single-handed ergonomic delivery mechanism
- Merit's initial entry into vascular stent market

Initiatives

- Utilize the stent graft technology platform to expand indications for use
- Establish world class centers of excellence with prominent key opinion leaders
- Deliver stent graft training and education programs to increase physician engagement

Cardiac Intervention Electrophysiology



Market
Opportunity
\$305M


Portfolio Priorities

- Pacing Lead Introduction— Classic Sheath™, Prelude Snap™
- Left Ventricular Lead Delivery – Worley™ Advanced LV Lead Delivery System
- Electrophysiology Diagnostic & Ablation Therapies—HeartSpan® Steerable and fixed curve sheaths, and transeptal needles

Initiatives

- Portfolio Revitalization & Differentiation – Launching 4 new products in 2015
- Geographic Expansion – Launching electrophysiology portfolio into 27 new countries
- Clinical Program Education – Global interventional technique training to electrophysiologists

Cardiac Intervention ThinkRadial™ Program



Health Care Economics

- Cost savings and patient preference drive adoption of radial access

Clinical Program Development

- Provide ThinkRadial training program to physicians

Portfolio Optimization

- Deliver full solution of radial products across the workflow to enable adoption

Market
Opportunity
\$365M

Financial Business Drivers

Sales NON-GAAP

2014
\$510M

2015
\$535M-\$545M

2016
\$580M-\$590M

2017
\$625M-\$635M

Financial Business Drivers
Gross Margins NON-GAAP

2014
46.4%

2015
46.5%-47.5%

2016
47.0%-48.0%

2017
47.8%-48.8%

Financial Business Drivers

Income from Operations NON-GAAP

2014
11.1%

2015
10.9%-11.9%

2016
11.5%-12.5%

2017
12.4%-13.4%

Financial Business Drivers

EPS NON-GAAP

2014
\$0.78

2015
\$0.85-\$0.89

2016
\$0.95-\$1.01

2017
\$1.10-\$1.18

Financial Business Drivers
EBITDA NON-GAAP

2014
\$78.1M

2015
\$84M-\$88M

2016
\$90M-\$96M

2017
\$98M-\$106M

Financial Business Drivers
Free Cash Flow NON-GAAP

2014
\$19M

2015
\$20M-\$25M

2016
\$30M-\$35M

2017
\$35M-\$40M

Financial Business Drivers

NON-GAAP

	2014	2015	2016	2017
Sales	\$510M	\$535M-\$545M	\$580M-\$590M	\$625M-\$635M
Gross Margin	46.4%	46.5%-47.5%	47.0%-48.0%	47.8%-48.8%
Income From Operations	11.1%	10.9%-11.9%	11.5%-12.5%	12.4%-13.4%
EPS	\$0.78	\$0.85-\$0.89	\$0.95-\$1.01	\$1.10-\$1.18
EBITDA	\$78.1M	\$84M-\$88M	\$90M-\$96M	\$98M-\$106M
Free Cash Flow	\$19M	\$20M-\$25M	\$30M-\$35M	\$35M-\$40M

Financial Business Drivers

GAAP

	2014	2015	2016	2017
Sales	\$510M	\$535M-\$545M	\$580M-\$590M	\$625M-\$635M
Gross Margin	44.2%	44.5%-45.5%	45.1%-46.1%	46.0%-47.0%
Income From Operations	7.9%	8.2%-9.2%	9.0%-10.0%	10.2%-11.2%
EPS	\$0.53	\$0.63-\$0.67	\$0.74-\$0.80	\$0.91-\$0.99
EBITDA	\$78.1M	\$84M-\$88M	\$90M-\$96M	\$98M-\$106M
Free Cash Flow	\$19M	\$20M-\$25M	\$30M-\$35M	\$35M-\$40M

VISION. GROWTH. PROFITABILITY.

1

Enhance growth and profitability

Through R&D, sales model optimization, cost discipline, and operational focus

2

Optimize operational capability

Through lean processes, cost effective environments, and asset utilization

3

Target high-growth, high-return opportunities

Through understanding, innovating, and delivering in peripheral, cardiac, OEM, and endoscopy business lines

4

Disciplined, customer-focused enterprise

Guided by strong core values to globally address unmet or underserved healthcare needs



Understand. Innovate. Deliver.™
